Richard C. Malabre, SVP and Chief Accounting Officer at Akebia Therapeutics ($AKBA), made four open market sales of company shares over the past year, totaling about $176 thousand. His most recent sale occurred on February 2, 2026. These transactions rank 8,704th among 11,678 insiders in our database, well below the average sale value of $8.6 million across about 6.4 transactions per insider. Malabre recorded no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 2, 2026 | Akebia Therapeutics, Inc. | $AKBA | Malabre Richard C | SVP, Chief Accounting Officer | S | Common Stock | 36142 | $1.39 | 312,772.0000 | 274,372,722 | 10.36% | 0.01% |
| Feb. 2, 2026 | Akebia Therapeutics, Inc. | $AKBA | Malabre Richard C | SVP, Chief Accounting Officer | S | Common Stock | 13382 | $1.39 | 299,390.0000 | 274,372,722 | 4.28% | 0.00% |
| Jan. 30, 2026 | Akebia Therapeutics, Inc. | $AKBA | Malabre Richard C | SVP, Chief Accounting Officer | A | Stock Option (Right to buy) | 119000 | $0.00 | 119,000.0000 | 274,372,722 | 9999.99% | 0.04% |
| Jan. 30, 2026 | Akebia Therapeutics, Inc. | $AKBA | Malabre Richard C | SVP, Chief Accounting Officer | A | Common Stock | 79000 | $0.00 | 348,914.0000 | 274,372,722 | 29.27% | 0.03% |
| June 9, 2025 | Akebia Therapeutics, Inc. | $AKBA | Malabre Richard C | SVP, Chief Accounting Officer | M | Common Stock | 15000 | $1.68 | 281,914.0000 | 210,946,658 | 5.62% | 0.01% |
| June 9, 2025 | Akebia Therapeutics, Inc. | $AKBA | Malabre Richard C | SVP, Chief Accounting Officer | S | Common Stock | 15000 | $4.01 | 266,914.0000 | 210,946,658 | 5.32% | 0.01% |
| June 9, 2025 | Akebia Therapeutics, Inc. | $AKBA | Malabre Richard C | SVP, Chief Accounting Officer | M | Stock Option (Right to buy) | 15000 | $0.00 | 321,000.0000 | 210,946,658 | 4.46% | 0.01% |
| June 4, 2025 | Akebia Therapeutics, Inc. | $AKBA | Malabre Richard C | SVP, Chief Accounting Officer | S | Common Stock | 13334 | $3.53 | 266,914.0000 | 210,946,658 | 4.76% | 0.01% |
| Jan. 31, 2025 | Akebia Therapeutics, Inc. | $AKBA | Malabre Richard C | SVP, Chief Accounting Officer | A | Stock Option (Right to buy) | 128000 | $0.00 | 128,000.0000 | 210,946,658 | 9999.99% | 0.06% |
| Feb. 3, 2025 | Akebia Therapeutics, Inc. | $AKBA | Malabre Richard C | SVP, Chief Accounting Officer | S | Common Stock | 30202 | $2.10 | 280,248.0000 | 210,946,658 | 9.73% | 0.01% |
| Jan. 31, 2025 | Akebia Therapeutics, Inc. | $AKBA | Malabre Richard C | SVP, Chief Accounting Officer | A | Common Stock | 85000 | $0.00 | 310,450.0000 | 210,946,658 | 37.70% | 0.04% |
| Jan. 31, 2024 | Akebia Therapeutics, Inc. | $AKBA | Malabre Richard C | Chief Accounting Officer | A | Common Stock | 223950 | $0.00 | 223,950.0000 | 187,465,448 | 9999.99% | 0.12% |
| Jan. 31, 2024 | Akebia Therapeutics, Inc. | $AKBA | Malabre Richard C | Chief Accounting Officer | A | Stock Option (Right to buy) | 336000 | $0.00 | 336,000.0000 | 187,465,448 | 9999.99% | 0.18% |